BACKGROUND: This study examined whether positron emission tomography (PET) studies with [18F] fallypride performed before and after alpha-methyl-para-tyrosine (AMPT) administration can be used to estimate baseline dopamine (DA) D2 receptor occupancy in striatal and extrastriatal regions. METHODS: Six normal subjects underwent PET with [18 F] fallypride before and after administration of AMPT. The DA D2 receptor binding potentials (bp) were calculated with the reference region method. Percent changes in bp in striatal and extrastriatal regions were calculated with both region-of-interest analysis and on a voxel by voxel basis with parametric images of DA D2 receptor levels. RESULTS: The results of the current study indicate that AMPT treatment significantly increased the bp in the caudate, putamen, ventral striatum, and substantia nigra. A trend level increase was seen in the medial thalamus. CONCLUSIONS: This study demonstrates that PET with [18F] fallypride can be used to estimate baseline DA D2 receptor occupancy in striatal and extrastriatal regions.
BACKGROUND: This study examined whether positron emission tomography (PET) studies with [18F] fallypride performed before and after alpha-methyl-para-tyrosine (AMPT) administration can be used to estimate baseline dopamine (DA) D2 receptor occupancy in striatal and extrastriatal regions. METHODS: Six normal subjects underwent PET with [18 F] fallypride before and after administration of AMPT. The DA D2 receptor binding potentials (bp) were calculated with the reference region method. Percent changes in bp in striatal and extrastriatal regions were calculated with both region-of-interest analysis and on a voxel by voxel basis with parametric images of DA D2 receptor levels. RESULTS: The results of the current study indicate that AMPT treatment significantly increased the bp in the caudate, putamen, ventral striatum, and substantia nigra. A trend level increase was seen in the medial thalamus. CONCLUSIONS: This study demonstrates that PET with [18F] fallypride can be used to estimate baseline DA D2 receptor occupancy in striatal and extrastriatal regions.
Authors: Julia P Dunn; Ronald L Cowan; Nora D Volkow; Irene D Feurer; Rui Li; D Brandon Williams; Robert M Kessler; Naji N Abumrad Journal: Brain Res Date: 2010-03-31 Impact factor: 3.252
Authors: Amira K Brown; Mark A Mandelkern; Judah Farahi; Chelsea Robertson; Dara G Ghahremani; Brittany Sumerel; Nathasha Moallem; Edythe D London Journal: Int J Neuropsychopharmacol Date: 2012-01-16 Impact factor: 5.176
Authors: Kenji Ishibashi; Chelsea L Robertson; Mark A Mandelkern; Andrew T Morgan; Edythe D London Journal: Mol Imaging Date: 2013 Nov-Dec Impact factor: 4.488
Authors: David H Zald; Neil D Woodward; Ronald L Cowan; Patrizia Riccardi; M Sib Ansari; Ronald M Baldwin; Ronald L Cowan; Clarence E Smith; Helene Hakyemez; Rui Li; Robert M Kessler Journal: Neuroimage Date: 2010-02-10 Impact factor: 6.556
Authors: Andrea Kobiella; Sabine Vollstädt-Klein; Mira Bühler; Caroline Graf; Hans-Georg Buchholz; Nina Bernow; Igor Y Yakushev; Christian Landvogt; Mathias Schreckenberger; Gerhard Gründer; Peter Bartenstein; Christoph Fehr; Michael N Smolka Journal: Hum Brain Mapp Date: 2010-05 Impact factor: 5.038
Authors: Fernando Caravaggio; Lawrence S Kegeles; Alan A Wilson; Gary Remington; Carol Borlido; David C Mamo; Ariel Graff-Guerrero Journal: Synapse Date: 2016-07-11 Impact factor: 2.562
Authors: Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham Journal: Biol Psychiatry Date: 2016-03-31 Impact factor: 13.382